Targeting Bone Marrow Small Non-coding RNAs in Cancer

View/ Open
Author(s)
Primary Supervisor
Mellick, Albert
Other Supervisors
Griffiths, Lyn
Forwood, Mark
McMillan, Nigel
Year published
2013
Metadata
Show full item recordAbstract
Cancer is one of the leading causes of death worldwide. Despite extensive research cancer is predicated to be the leading cause of death by 2020. One element of cancer development, which has been successfully targeted clinically resulting in impaired tumour growth and spread (metastases), is the process by which tumours enroll vasculature. This is referred to as tumour angiogenesis. However, the problems currently associated with current anti-angiogenic therapies (eg. Avastin) is that they are prone to adaptive resistance (the process of initial response, followed by hypoxia and rapid relapse). Furthermore, such therapies ...
View more >Cancer is one of the leading causes of death worldwide. Despite extensive research cancer is predicated to be the leading cause of death by 2020. One element of cancer development, which has been successfully targeted clinically resulting in impaired tumour growth and spread (metastases), is the process by which tumours enroll vasculature. This is referred to as tumour angiogenesis. However, the problems currently associated with current anti-angiogenic therapies (eg. Avastin) is that they are prone to adaptive resistance (the process of initial response, followed by hypoxia and rapid relapse). Furthermore, such therapies target normal aspects of human biology, including the immune system, wound healing and vascular homeostasis. This leads to unintended and adverse side-affects. Bone marrow (BM) derived Endothelial Progenitor Cells (EPCs) play a critical role in tumour angiogenesis and adaptive resistance. Therefore, targeting these cells offers a novel anti-angiogenic therapy, which may not be associated with the problems of current treatments.
View less >
View more >Cancer is one of the leading causes of death worldwide. Despite extensive research cancer is predicated to be the leading cause of death by 2020. One element of cancer development, which has been successfully targeted clinically resulting in impaired tumour growth and spread (metastases), is the process by which tumours enroll vasculature. This is referred to as tumour angiogenesis. However, the problems currently associated with current anti-angiogenic therapies (eg. Avastin) is that they are prone to adaptive resistance (the process of initial response, followed by hypoxia and rapid relapse). Furthermore, such therapies target normal aspects of human biology, including the immune system, wound healing and vascular homeostasis. This leads to unintended and adverse side-affects. Bone marrow (BM) derived Endothelial Progenitor Cells (EPCs) play a critical role in tumour angiogenesis and adaptive resistance. Therefore, targeting these cells offers a novel anti-angiogenic therapy, which may not be associated with the problems of current treatments.
View less >
Thesis Type
Thesis (PhD Doctorate)
Degree Program
Doctor of Philosophy (PhD)
School
School of Medical Science
Copyright Statement
The author owns the copyright in this thesis, unless stated otherwise.
Item Access Status
Public
Subject
Tumour angiogenesis
Endothelial progenitor cells (EPCs)
Cancer research
Bone marrow small non-coding RNAs
Ribonucleic acid